August 30, 2017. Framingham, MA.
Variantyx today announced integration of its clinical whole genome testing pipeline with FDNA’s Face2Gene suite of applications. Using its proprietary Genomic Intelligence® platform, Variantyx provides end-to-end clinical diagnostic services for rare genetic disorders based on comprehensive whole genome sequencing (WGS). Integration with Face2Gene technology now enables clinicians worldwide to send information about the phenotypes, syndromes and genes that correlate with a patient’s facial and clinical analysis to Variantyx directly, speeding analysis and improving variant interpretation.